Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,4096611,half-life,"The half-life of Phy was found to be 21.6 +/- 1.8 min (mean +/- S.E.) as determined in bile, 52.1 +/- 9.1 min as determined from serum, and the systemic clearance of Phy was .63 +/- 2.6 ml/min.",Pharmacokinetics of biliary excretion of physostigmine in rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096611/),min,21.6,7694,DB00981,Physostigmine
,4096611,half-life,"The half-life of Phy was found to be 21.6 +/- 1.8 min (mean +/- S.E.) as determined in bile, 52.1 +/- 9.1 min as determined from serum, and the systemic clearance of Phy was .63 +/- 2.6 ml/min.",Pharmacokinetics of biliary excretion of physostigmine in rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096611/),min,52.1,7695,DB00981,Physostigmine
,4096611,systemic clearance,"The half-life of Phy was found to be 21.6 +/- 1.8 min (mean +/- S.E.) as determined in bile, 52.1 +/- 9.1 min as determined from serum, and the systemic clearance of Phy was .63 +/- 2.6 ml/min.",Pharmacokinetics of biliary excretion of physostigmine in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096611/),[ml] / [min],.63,7696,DB00981,Physostigmine
,4096611,Kel,The mean Kel was found to be .012 min-1.,Pharmacokinetics of biliary excretion of physostigmine in rat. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096611/),1/[min],.012,7697,DB00981,Physostigmine
,4096611,biliary excretion rate constant,The biliary excretion rate constant was determined to be .014 +/- .001 min-1 for total radioactivity and .008 +/- .002 min-1 for Phy.,Pharmacokinetics of biliary excretion of physostigmine in rat. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096611/),1/[min],.014,7698,DB00981,Physostigmine
,4096611,biliary excretion rate constant,The biliary excretion rate constant was determined to be .014 +/- .001 min-1 for total radioactivity and .008 +/- .002 min-1 for Phy.,Pharmacokinetics of biliary excretion of physostigmine in rat. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096611/),1/[min],.008,7699,DB00981,Physostigmine
,4096611,Biliary clearance,Biliary clearance of Phy was .18 ml/min.,Pharmacokinetics of biliary excretion of physostigmine in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096611/),[ml] / [min],.18,7700,DB00981,Physostigmine
,4096611,serum to bile ratio,"The serum to bile ratio of Phy at 15-30 min was 5.11, indicating rapid concentration of Phy in the bile.",Pharmacokinetics of biliary excretion of physostigmine in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096611/),,5.11,7701,DB00981,Physostigmine
,2273462,Apparent volumes of distribution,Apparent volumes of distribution (assuming 100% bioavailability) ranged from 1.9 to 2.2 L/kg.,Pharmacokinetics of physostigmine intramuscularly administered to guinea pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273462/),[l] / [kg],1.9 to 2.2,16552,DB00981,Physostigmine
,2273462,Systemic clearances,"Systemic clearances and elimination half-lives were 30-36 mL/min/kg and 40-50 min, respectively.",Pharmacokinetics of physostigmine intramuscularly administered to guinea pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273462/),[ml] / [kg·min],30-36,16553,DB00981,Physostigmine
,2273462,elimination half-lives,"Systemic clearances and elimination half-lives were 30-36 mL/min/kg and 40-50 min, respectively.",Pharmacokinetics of physostigmine intramuscularly administered to guinea pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273462/),min,40-50,16554,DB00981,Physostigmine
,10703994,limit of detection,The calibration graph was linear over the calibration range 0.2-12 microg ml(-1) plasma with a limit of detection of 0.1 microg ml(-1).,A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10703994/),[μg] / [ml],0.1,23623,DB00981,Physostigmine
,7480518,peak plasma concentrations,"Pharmacokinetic analysis following administration of 4 or 6 mg/kg velnacrine to three aged monkeys revealed peak plasma concentrations ranging from 27 to 166 ng/ml, 30-60 min after dosing.",Velnacrine maleate improves delayed matching performance by aged monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7480518/),[ng] / [ml],27 to 166,40200,DB00981,Physostigmine
,12505780,flow-rate,"Physostigmine and eseroline were separated on an Alltech Ultrasphere Silica column (250x4.6 mm I.D.; particle size 5 micrometer) at a flow-rate of 1 ml/min, with a mobile phase of 0.01 M sodium dihydrogenphosphate (pH 3)-acetonitrile (85:15).",Simple liquid chromatographic method for the determination of physostigmine and its metabolite eseroline in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12505780/),[ml] / [min],1,41975,DB00981,Physostigmine
,12505780,limits of detection,"The limits of detection were 10 and 25 ng/ml for physostigmine and eseroline, respectively; the signal-to-noise ratio for this concentration was approximately 3:1.",Simple liquid chromatographic method for the determination of physostigmine and its metabolite eseroline in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12505780/),[ng] / [ml],10,41976,DB00981,Physostigmine
,12505780,limits of detection,"The limits of detection were 10 and 25 ng/ml for physostigmine and eseroline, respectively; the signal-to-noise ratio for this concentration was approximately 3:1.",Simple liquid chromatographic method for the determination of physostigmine and its metabolite eseroline in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12505780/),[ng] / [ml],25,41977,DB00981,Physostigmine
,12505780,signal-to-noise ratio,"The limits of detection were 10 and 25 ng/ml for physostigmine and eseroline, respectively; the signal-to-noise ratio for this concentration was approximately 3:1.",Simple liquid chromatographic method for the determination of physostigmine and its metabolite eseroline in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12505780/),,3:1,41978,DB00981,Physostigmine
,12505780,percentage recovery,"The average percentage recovery from five spiked plasma samples was 88.0+/-2.9 and 61.1+/-5.6% for physostigmine and eseroline, respectively.",Simple liquid chromatographic method for the determination of physostigmine and its metabolite eseroline in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12505780/),%,88.0,41979,DB00981,Physostigmine
,12505780,percentage recovery,"The average percentage recovery from five spiked plasma samples was 88.0+/-2.9 and 61.1+/-5.6% for physostigmine and eseroline, respectively.",Simple liquid chromatographic method for the determination of physostigmine and its metabolite eseroline in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12505780/),%,61.1,41980,DB00981,Physostigmine
,3349492,t1/2 alpha,"Pharmacokinetic evaluation of SHM revealed a t1/2 alpha of 1.7 +/- 0.7 min, t1/2 beta of 16 +/- 8.3 min, and total body clearance of 2134 +/- 735 ml/min/m2.",A pediatric phase I and pharmacokinetic study of spirohydantoin mustard. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349492/),min,1.7,51956,DB00981,Physostigmine
,3349492,t1/2 beta,"Pharmacokinetic evaluation of SHM revealed a t1/2 alpha of 1.7 +/- 0.7 min, t1/2 beta of 16 +/- 8.3 min, and total body clearance of 2134 +/- 735 ml/min/m2.",A pediatric phase I and pharmacokinetic study of spirohydantoin mustard. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349492/),min,16,51957,DB00981,Physostigmine
,3349492,total body clearance,"Pharmacokinetic evaluation of SHM revealed a t1/2 alpha of 1.7 +/- 0.7 min, t1/2 beta of 16 +/- 8.3 min, and total body clearance of 2134 +/- 735 ml/min/m2.",A pediatric phase I and pharmacokinetic study of spirohydantoin mustard. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349492/),[ml] / [m2·min],2134,51958,DB00981,Physostigmine
less,3349492,cerebrospinal fluid to plasma ratios,SHM cerebrospinal fluid to plasma ratios were less than 0.047.,A pediatric phase I and pharmacokinetic study of spirohydantoin mustard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349492/),,0.047,51959,DB00981,Physostigmine
,2810113,apparent volume of distribution,"The results were as follows: apparent volume of distribution = 5.9 liters/kg, absorption rate half-life = 2.7 min.",Development and application of a radioimmunoassay for physostigmine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810113/),[l] / [kg],5.9,59647,DB00981,Physostigmine
,2810113,absorption rate half-life,"The results were as follows: apparent volume of distribution = 5.9 liters/kg, absorption rate half-life = 2.7 min.",Development and application of a radioimmunoassay for physostigmine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810113/),min,2.7,59648,DB00981,Physostigmine
,2810113,elimination rate half-life,"elimination rate half-life = 17.4 min, area under the curve = 118 ng x min/ml, maximal plasma concentration = 3.5 ng/ml and time to maximal plasma concentration = 7.7 min.",Development and application of a radioimmunoassay for physostigmine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810113/),min,17.4,59649,DB00981,Physostigmine
,2810113,area under the curve,"elimination rate half-life = 17.4 min, area under the curve = 118 ng x min/ml, maximal plasma concentration = 3.5 ng/ml and time to maximal plasma concentration = 7.7 min.",Development and application of a radioimmunoassay for physostigmine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810113/),[min·ng] / [ml],118,59650,DB00981,Physostigmine
,2810113,maximal plasma concentration,"elimination rate half-life = 17.4 min, area under the curve = 118 ng x min/ml, maximal plasma concentration = 3.5 ng/ml and time to maximal plasma concentration = 7.7 min.",Development and application of a radioimmunoassay for physostigmine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810113/),[ng] / [ml],3.5,59651,DB00981,Physostigmine
,2810113,time to maximal plasma concentration,"elimination rate half-life = 17.4 min, area under the curve = 118 ng x min/ml, maximal plasma concentration = 3.5 ng/ml and time to maximal plasma concentration = 7.7 min.",Development and application of a radioimmunoassay for physostigmine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810113/),min,7.7,59652,DB00981,Physostigmine
,1791534,nasal bioavailability,"Physostigmine nasal bioavailability was 100% as compared with iv bioavailability, and that of arecoline was 85% when compared with bioavailability following im administration.",Intranasal absorption of physostigmine and arecoline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1791534/),%,100,64189,DB00981,Physostigmine
,1791534,nasal bioavailability,"Physostigmine nasal bioavailability was 100% as compared with iv bioavailability, and that of arecoline was 85% when compared with bioavailability following im administration.",Intranasal absorption of physostigmine and arecoline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1791534/),%,85,64190,DB00981,Physostigmine
,3699321,half-life,"The half-life of Phy in plasma and brain was 17 and 16 min, respectively.",Distribution and pharmacokinetics of physostigmine in rat after intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3699321/),min,17,74045,DB00981,Physostigmine
,3699321,half-life,"The half-life of Phy in plasma and brain was 17 and 16 min, respectively.",Distribution and pharmacokinetics of physostigmine in rat after intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3699321/),min,16,74046,DB00981,Physostigmine
,3699321,brain-to-plasma ratio,The brain-to-plasma ratio of Phy peaked (1.61) at 22 min.,Distribution and pharmacokinetics of physostigmine in rat after intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3699321/),,1.61,74047,DB00981,Physostigmine
,3699321,peak plasma concentration,Phy concentration showed that the maximum enzymatic inhibition (47%) occurred at about the same time (7 min) as the peak plasma concentration (583 ng/ml at 5 min).,Distribution and pharmacokinetics of physostigmine in rat after intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3699321/),[ng] / [ml],583,74048,DB00981,Physostigmine
,2778001,Extraction efficiency,Extraction efficiency was 99.6%.,Application of a new radiometric high-performance liquid chromatographic assay to define physostigmine pharmacokinetics in guinea pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778001/),%,99.6,80353,DB00981,Physostigmine
,2778001,maximum serum concentration,Physostigmine (5 micrograms/kg) intramuscularly administered to the guinea pig (n = 6) reached maximum serum concentration (1.5 ng/ml) in 26 min.,Application of a new radiometric high-performance liquid chromatographic assay to define physostigmine pharmacokinetics in guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778001/),[ng] / [ml],1.5,80354,DB00981,Physostigmine
,2778001,apparent volume of distribution,"The apparent volume of distribution and systemic clearance were 1.4 l/kg and 26 ml/min/kg, respectively.",Application of a new radiometric high-performance liquid chromatographic assay to define physostigmine pharmacokinetics in guinea pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778001/),[l] / [kg],1.4,80355,DB00981,Physostigmine
,2778001,systemic clearance,"The apparent volume of distribution and systemic clearance were 1.4 l/kg and 26 ml/min/kg, respectively.",Application of a new radiometric high-performance liquid chromatographic assay to define physostigmine pharmacokinetics in guinea pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778001/),[ml] / [kg·min],26,80356,DB00981,Physostigmine
,2706318,absorption rate constant (ka),"The absorption rate constant (ka) and elimination rate constant (ke) were found to be 0.1 +/- 0.07 min-1 and 0.036 +/- 0.024 min-1, respectively.",Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),1/[min],0.1,80629,DB00981,Physostigmine
,2706318,elimination rate constant (ke),"The absorption rate constant (ka) and elimination rate constant (ke) were found to be 0.1 +/- 0.07 min-1 and 0.036 +/- 0.024 min-1, respectively.",Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),1/[min],0.036,80630,DB00981,Physostigmine
,2706318,Cpmax,Cpmax and tmax were 3.3 ng ml-1 and 16 min.,Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),[ng] / [ml],3.3,80631,DB00981,Physostigmine
,2706318,tmax,Cpmax and tmax were 3.3 ng ml-1 and 16 min.,Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),min,16,80632,DB00981,Physostigmine
,2706318,clearance (C1),The clearance (C1) was found to be 80.9 ml min-1kg-1.,Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),[ml] / [min],80.9,80633,DB00981,Physostigmine
,2706318,Half-life,"Half-life of Phy in brain, muscle, and liver were 33.4 min, 22.5, and 28 min, respectively.",Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),min,33.4,80634,DB00981,Physostigmine
,2706318,Half-life,"Half-life of Phy in brain, muscle, and liver were 33.4 min, 22.5, and 28 min, respectively.",Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),min,22.5,80635,DB00981,Physostigmine
,2706318,Half-life,"Half-life of Phy in brain, muscle, and liver were 33.4 min, 22.5, and 28 min, respectively.",Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),min,28,80636,DB00981,Physostigmine
,2706318,bioavailability (F),The bioavailability (F) was calculated to be 0.02 and the extraction ratio was found to be 0.98 indicating the 'first pass' effect.,Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),,0.02,80637,DB00981,Physostigmine
,2706318,extraction ratio,The bioavailability (F) was calculated to be 0.02 and the extraction ratio was found to be 0.98 indicating the 'first pass' effect.,Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),,0.98,80638,DB00981,Physostigmine
,2706318,activity,Butyrylcholinesterase activity in plasma was 76 per cent at 15 min and this activity did not change significantly up to 120 min.,Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),%,76,80639,DB00981,Physostigmine
,2706318,Phy,"However, Phy concentration in plasma was very low; 2.89 ng ml-1 at 15 min and declined to 0.71 ng ml-1 at 90 min.",Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),[ng] / [ml],2.89,80640,DB00981,Physostigmine
,2706318,Phy,"However, Phy concentration in plasma was very low; 2.89 ng ml-1 at 15 min and declined to 0.71 ng ml-1 at 90 min.",Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),[ng] / [ml],0.71,80641,DB00981,Physostigmine
,2706318,concentration,"However, Phy concentration in plasma was very low; 2.89 ng ml-1 at 15 min and declined to 0.71 ng ml-1 at 90 min.",Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),[ng] / [ml],2.89,80642,DB00981,Physostigmine
,2706318,concentration,"However, Phy concentration in plasma was very low; 2.89 ng ml-1 at 15 min and declined to 0.71 ng ml-1 at 90 min.",Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),[ng] / [ml],0.71,80643,DB00981,Physostigmine
,2706318,concentration in brain,Physostigmine concentration in brain peaked at 22 min to 2.85 +/- 1.09 ng g-1 and declined to 0.33 +/- 0.11 ng g-1 at 60 min.,Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),[ng] / [g],2.85,80644,DB00981,Physostigmine
,2706318,concentration in brain,Physostigmine concentration in brain peaked at 22 min to 2.85 +/- 1.09 ng g-1 and declined to 0.33 +/- 0.11 ng g-1 at 60 min.,Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),[ng] / [g],0.33,80645,DB00981,Physostigmine
,2706318,Cho,"Cholinesterase activity in brain was 96 per cent, 82 per cent and 89 per cent at 10, 45, and 120 min, respectively.",Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),%,96,80646,DB00981,Physostigmine
,2706318,Cho,"Cholinesterase activity in brain was 96 per cent, 82 per cent and 89 per cent at 10, 45, and 120 min, respectively.",Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),%,82,80647,DB00981,Physostigmine
,2706318,Cho,"Cholinesterase activity in brain was 96 per cent, 82 per cent and 89 per cent at 10, 45, and 120 min, respectively.",Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706318/),%,89,80648,DB00981,Physostigmine
,31398669,plasma concentrations,Steady state physostigmine plasma concentrations reached 7.60 ± 2.81 ng/mL (mean ± standard deviation [SD]).,Continuous infusion of physostigmine in patients with perioperative septic shock: A pharmacokinetic/pharmacodynamic study with population pharmacokinetic modeling. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31398669/),[ng] / [ml],7.60,94200,DB00981,Physostigmine
,31398669,half maximal effective concentration (EC50),"A sigmoidal direct effect PD model best described enzyme inhibition by physostigmine, with an estimated half maximal effective concentration (EC50) of 5.99 ng/mL.",Continuous infusion of physostigmine in patients with perioperative septic shock: A pharmacokinetic/pharmacodynamic study with population pharmacokinetic modeling. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31398669/),[ng] / [ml],5.99,94201,DB00981,Physostigmine
,11920924,inhibition,Whole-blood cholinesterase inhibition was 15-20%.,Prophylaxis against organophosphate poisoning by sustained release of scopolamine and physostigmine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920924/),%,15-20,99111,DB00981,Physostigmine
,6446831,half-life,In vitro experiments showed that thymoxamine had a half-life in human plasma of about only 1 min.,Plasma induced biotransformation of thymoxamine and its kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6446831/),min,1,101428,DB00981,Physostigmine
,6446831,Km,A Km-value of about 0.115 mumol ml-1 and a Vm-value of about 0.0037 mumol ml-1 min.-1 were found.,Plasma induced biotransformation of thymoxamine and its kinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6446831/),[μM] / [ml],0.115,101429,DB00981,Physostigmine
,6446831,Vm,A Km-value of about 0.115 mumol ml-1 and a Vm-value of about 0.0037 mumol ml-1 min.-1 were found.,Plasma induced biotransformation of thymoxamine and its kinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6446831/),[-1·min·μM] / [ml],0.0037,101430,DB00981,Physostigmine
,25565546,recovery,LLE produced clean extracts and a mean recovery of 80.3% for eseroline and 84.9% for physostigmine.,Revival of physostigmine - a novel HPLC assay for simultaneous determination of physostigmine and its metabolite eseroline designed for a pharmacokinetic study of septic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25565546/),%,80.3,103087,DB00981,Physostigmine
,25565546,recovery,LLE produced clean extracts and a mean recovery of 80.3% for eseroline and 84.9% for physostigmine.,Revival of physostigmine - a novel HPLC assay for simultaneous determination of physostigmine and its metabolite eseroline designed for a pharmacokinetic study of septic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25565546/),%,84.9,103088,DB00981,Physostigmine
,25565546,limit of detection (LOD),The HPLC assay revealed a limit of detection (LOD) of 0.025 ng/mL and a lower limit of quantification (LLOQ) of 0.05 ng/mL for both analytes.,Revival of physostigmine - a novel HPLC assay for simultaneous determination of physostigmine and its metabolite eseroline designed for a pharmacokinetic study of septic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25565546/),[ng] / [ml],0,103089,DB00981,Physostigmine
,19290944,protective times,"Group median protective times for the first regimen were 54.45 h for SCO and 64.35 h for PHY, and for the second regimen 63.75 h for SCO and 0 h for PHY.",Evaluation of two scopolamine and physostigmine pretreatment regimens against nerve agent poisoning in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19290944/),h,54.45,105109,DB00981,Physostigmine
,19290944,protective times,"Group median protective times for the first regimen were 54.45 h for SCO and 64.35 h for PHY, and for the second regimen 63.75 h for SCO and 0 h for PHY.",Evaluation of two scopolamine and physostigmine pretreatment regimens against nerve agent poisoning in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19290944/),h,64.35,105110,DB00981,Physostigmine
,19290944,protective times,"Group median protective times for the first regimen were 54.45 h for SCO and 64.35 h for PHY, and for the second regimen 63.75 h for SCO and 0 h for PHY.",Evaluation of two scopolamine and physostigmine pretreatment regimens against nerve agent poisoning in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19290944/),h,63.75,105111,DB00981,Physostigmine
,19290944,protective times,"Group median protective times for the first regimen were 54.45 h for SCO and 64.35 h for PHY, and for the second regimen 63.75 h for SCO and 0 h for PHY.",Evaluation of two scopolamine and physostigmine pretreatment regimens against nerve agent poisoning in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19290944/),h,0,105112,DB00981,Physostigmine
,2039641,Plasma clearance (C1),"Plasma clearance (C1) was high and showed a twofold inter-individual variation, with a mean of 2.64 +/- 1.17 L/h.","Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),[l] / [h],2.64,105731,DB00981,Physostigmine
,2039641,Volume of distribution (Vd gamma),"Volume of distribution (Vd gamma) varied between 300 and 850 liters, with a mean of 477 +/- 185 liters.","Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),l,477,105732,DB00981,Physostigmine
,2039641,plasma half-lives,"The plasma half-lives of rapid and slow distribution, and elimination were 2.1 +/- 0.7 minutes, 26 +/- 18 minutes, and 133 +/- 48 minutes, respectively.","Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),min,2.1,105733,DB00981,Physostigmine
,2039641,plasma half-lives,"The plasma half-lives of rapid and slow distribution, and elimination were 2.1 +/- 0.7 minutes, 26 +/- 18 minutes, and 133 +/- 48 minutes, respectively.","Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),min,26,105734,DB00981,Physostigmine
,2039641,plasma half-lives,"The plasma half-lives of rapid and slow distribution, and elimination were 2.1 +/- 0.7 minutes, 26 +/- 18 minutes, and 133 +/- 48 minutes, respectively.","Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),min,133,105735,DB00981,Physostigmine
,2039641,elimination,"The plasma half-lives of rapid and slow distribution, and elimination were 2.1 +/- 0.7 minutes, 26 +/- 18 minutes, and 133 +/- 48 minutes, respectively.","Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),min,2.1,105736,DB00981,Physostigmine
,2039641,elimination,"The plasma half-lives of rapid and slow distribution, and elimination were 2.1 +/- 0.7 minutes, 26 +/- 18 minutes, and 133 +/- 48 minutes, respectively.","Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),min,133,105737,DB00981,Physostigmine
,2039641,Maximum plasma concentrations,Maximum plasma concentrations of 1-hydroxy-THA were 27 to 90 ng/ml in five patients; the concentration was below 1 ng/ml in two other patients.,"Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),[ng] / [ml],27 to 90,105738,DB00981,Physostigmine
below,2039641,Maximum plasma concentrations,Maximum plasma concentrations of 1-hydroxy-THA were 27 to 90 ng/ml in five patients; the concentration was below 1 ng/ml in two other patients.,"Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),[ng] / [ml],1,105739,DB00981,Physostigmine
,2589000,constant plasma concentration,"In order to antagonize immediate postoperative somnolence, 24 surgical patients were given a two-rate infusion of physostigmine, aiming at a constant plasma concentration in the range of 1 to 10 ng/ml.",Reversal of postoperative somnolence using a two-rate infusion of physostigmine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589000/),[ng] / [ml],1 to 10,116187,DB00981,Physostigmine
,2589000,Clearance,Clearance varied between 10 and 85 ml/min x kg with a mean of 40.8 +/- 21.0 ml/min x kg.,Reversal of postoperative somnolence using a two-rate infusion of physostigmine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589000/),[ml] / [kg·min],40.8,116188,DB00981,Physostigmine
,2589000,Oral bioavailability,Oral bioavailability was 25.3 +/- 11.1%.,Reversal of postoperative somnolence using a two-rate infusion of physostigmine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589000/),%,25.3,116189,DB00981,Physostigmine
,10551971,elimination half-life,The calculated elimination half-life was 10.2 h and the molecule and/or its metabolites were found up to 90 h after ingestion.,Orphenadrine poisoning in a child: clinical and analytical data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551971/),h,10.2,119192,DB00981,Physostigmine
,3524957,Plasma clearances,Plasma clearances of the reversible quaternary cholinesterase inhibitors are in the range 0.5 to 1.0 L/h/kg and their apparent volumes of distribution range from 0.5 to 1.7 L/kg.,Clinical pharmacokinetics of cholinesterase inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),[l] / [h·kg],0.5 to 1.0,120227,DB00981,Physostigmine
,3524957,apparent volumes of distribution,Plasma clearances of the reversible quaternary cholinesterase inhibitors are in the range 0.5 to 1.0 L/h/kg and their apparent volumes of distribution range from 0.5 to 1.7 L/kg.,Clinical pharmacokinetics of cholinesterase inhibitors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),[l] / [kg],0.5 to 1.7,120228,DB00981,Physostigmine
,3524957,plasma elimination half-lives,"Accordingly, the drugs have short plasma elimination half-lives, in the order of 30 to 90 minutes.",Clinical pharmacokinetics of cholinesterase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),min,30 to 90,120229,DB00981,Physostigmine
,3524957,peak plasma concentrations,"One to two hours after oral administration of 60 mg pyridostigmine, peak plasma concentrations of 40 to 60 micrograms/L are observed, whereas the plasma concentrations of neostigmine after a 30 mg oral dose are only 1 to 5 micrograms/L.",Clinical pharmacokinetics of cholinesterase inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),[μg] / [l],40 to 60,120230,DB00981,Physostigmine
,3524957,plasma concentrations,"One to two hours after oral administration of 60 mg pyridostigmine, peak plasma concentrations of 40 to 60 micrograms/L are observed, whereas the plasma concentrations of neostigmine after a 30 mg oral dose are only 1 to 5 micrograms/L.",Clinical pharmacokinetics of cholinesterase inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),[μg] / [l],1 to 5,120231,DB00981,Physostigmine
,3524957,oral bioavailability,The oral bioavailability of these hydrophilic ionised compounds is low: that of pyridostigmine is approximately 10% and the value for neostigmine is even lower.,Clinical pharmacokinetics of cholinesterase inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),%,10,120232,DB00981,Physostigmine
,3524957,plasma elimination half-life,This drug too is characterised by a short plasma elimination half-life of 20 to 30 minutes.,Clinical pharmacokinetics of cholinesterase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524957/),min,20 to 30,120233,DB00981,Physostigmine
,33891333,half-life,Pharmacokinetics of HTL0009936 showed dose-proportional increases in exposure with a mean half-life of 2.4 hours.,"Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M1 -acetylcholine receptor agonist: A randomized cross-over trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33891333/),h,2.4,120904,DB00981,Physostigmine
,3830722,cumulative percent of radioactivity excreted,"The cumulative percent of radioactivity excreted in the urine was 30.3 +/- 12.6% in 6 hr, 44.4 +/- 13.1% in 24 hr which increased to 52.7 +/- 12.0% after seven days.",Urinary pharmacokinetics of physostigmine in the rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830722/),%,30.3,122111,DB00981,Physostigmine
,3830722,cumulative percent of radioactivity excreted,"The cumulative percent of radioactivity excreted in the urine was 30.3 +/- 12.6% in 6 hr, 44.4 +/- 13.1% in 24 hr which increased to 52.7 +/- 12.0% after seven days.",Urinary pharmacokinetics of physostigmine in the rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830722/),%,44.4,122112,DB00981,Physostigmine
,3830722,cumulative percent of radioactivity excreted,"The cumulative percent of radioactivity excreted in the urine was 30.3 +/- 12.6% in 6 hr, 44.4 +/- 13.1% in 24 hr which increased to 52.7 +/- 12.0% after seven days.",Urinary pharmacokinetics of physostigmine in the rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830722/),%,52.7,122113,DB00981,Physostigmine
,3830722,Urinary elimination rate constant (Ku),Urinary elimination rate constant (Ku) of Phy was found to be .051 +/- .009 hr-1 indicating that the urinary elimination of Phy accounted for a minor part (2.5-4.%) of the systemic elimination.,Urinary pharmacokinetics of physostigmine in the rat. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830722/),1/[h],.051,122114,DB00981,Physostigmine
,7554703,elimination half-life,The elimination half-life of physostigmine was 16.4 +/- 3.2 (SE) minutes.,Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554703/),min,16.4,131101,DB00981,Physostigmine
,7554703,Clearance,"Clearance and volume of distribution were 7.7 +/- 0.9 (SE) L/min and 2.4 +/- 0.6 (SE) L/kg, respectively.",Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554703/),[l] / [min],7.7,131102,DB00981,Physostigmine
,7554703,volume of distribution,"Clearance and volume of distribution were 7.7 +/- 0.9 (SE) L/min and 2.4 +/- 0.6 (SE) L/kg, respectively.",Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554703/),[l] / [kg],2.4,131103,DB00981,Physostigmine
,7554703,inhibition half-life,Butyrylcholinesterase inhibition half-life was 83.7 +/- 5.2 (SE) minutes.,Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554703/),min,83.7,131104,DB00981,Physostigmine
,1784004,peak plasma concentration,"By contrast, the metabolite veratric acid achieved considerable concentrations (mean peak plasma concentration of 13.5 micrograms/mL at 40-80 min).",Facile hydrolysis of mebeverine in vitro and in vivo: negligible circulating concentrations of the drug after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1784004/),[μg] / [ml],13.5,133447,DB00981,Physostigmine
,1784004,half-life,"HCl (2 mg) to rats, the drug was rapidly eliminated from plasma (mean half-life of 29 min) with simultaneous appearance of veratric acid (mean peak plasma concentration of 1.80 micrograms/mL at 15-30 min).",Facile hydrolysis of mebeverine in vitro and in vivo: negligible circulating concentrations of the drug after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1784004/),min,29,133448,DB00981,Physostigmine
,1784004,peak plasma concentration,"HCl (2 mg) to rats, the drug was rapidly eliminated from plasma (mean half-life of 29 min) with simultaneous appearance of veratric acid (mean peak plasma concentration of 1.80 micrograms/mL at 15-30 min).",Facile hydrolysis of mebeverine in vitro and in vivo: negligible circulating concentrations of the drug after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1784004/),[μg] / [ml],1.80,133449,DB00981,Physostigmine
,1784004,peak plasma concentration,Veratric acid again achieved considerable concentrations (mean peak plasma concentration of 0.90 micrograms/mL at 15 min-4 h).,Facile hydrolysis of mebeverine in vitro and in vivo: negligible circulating concentrations of the drug after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1784004/),[μg] / [ml],0.90,133450,DB00981,Physostigmine
,4024217,Minimum concentrations,Minimum concentrations of 10 micrograms/L (aspirin) and 0.5 mg/L (salicylate) can be measured using 1 ml of plasma.,A sensitive liquid chromatographic assay for plasma aspirin and salicylate concentrations after low doses of aspirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024217/),[μg] / [l],10,152142,DB00981,Physostigmine
,4024217,Minimum concentrations,Minimum concentrations of 10 micrograms/L (aspirin) and 0.5 mg/L (salicylate) can be measured using 1 ml of plasma.,A sensitive liquid chromatographic assay for plasma aspirin and salicylate concentrations after low doses of aspirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024217/),[mg] / [l],0.5,152143,DB00981,Physostigmine
,8299673,maximum plasma cholinesterase inhibition,"The maximum plasma cholinesterase inhibition was 17%, which was reached 2.7 h after treatment.",Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8299673/),%,17,154746,DB00981,Physostigmine
,8299673,maximum inhibition,In red cells the maximum inhibition of the enzyme was 29% after 3.8 h.,Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8299673/),%,29,154747,DB00981,Physostigmine
,8299673,half-time of cholinesterase recovery,The estimated half-time of cholinesterase recovery was 12.4 h in plasma and 13.6 h in red blood cells.,Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8299673/),h,12.4,154748,DB00981,Physostigmine
,8299673,half-time of cholinesterase recovery,The estimated half-time of cholinesterase recovery was 12.4 h in plasma and 13.6 h in red blood cells.,Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8299673/),h,13.6,154749,DB00981,Physostigmine
,8299673,peak plasma concentration,The peak plasma concentration of eptastigmine of 0.86 ng.,Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8299673/),ng,0.86,154750,DB00981,Physostigmine
,8299673,t1/2 alpha,Following absorption the drug was rapidly distributed into tissues (t1/2 alpha = 0.44 h) and then eliminated with a half-life of 12.1 h.,Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8299673/),h,0.44,154751,DB00981,Physostigmine
,8299673,half-life,Following absorption the drug was rapidly distributed into tissues (t1/2 alpha = 0.44 h) and then eliminated with a half-life of 12.1 h.,Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8299673/),h,12.1,154752,DB00981,Physostigmine
,9789873,AUC0-24 h,AUC0-24 h was 245.2 +/- 337.2 h.ng/ml.,Development and in vivo assessment of a transdermal system for physostigmine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9789873/),[h·ng] / [ml],245.2,158496,DB00981,Physostigmine
,9789873,flux,"The mean pad flux reached 4.6 +/- 6.3 micrograms/cm2 from 0 to 24 h and, 24 h after the application of the pad, 110 micrograms/cm2 of PHY had been passed through the skin.",Development and in vivo assessment of a transdermal system for physostigmine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9789873/),[μg] / [cm2],4.6,158497,DB00981,Physostigmine
,9789873,plasma concentrations,"After removed of the patch, plasma concentrations first increased from 15.8 +/- 28.6 ng/ml (at 24 h) to 21.4 +/- 36.7 ng/ml, then decreased with an elimination half-life of 0.7 +/- 0.2 h.",Development and in vivo assessment of a transdermal system for physostigmine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9789873/),[ng] / [ml],15.8,158498,DB00981,Physostigmine
,9789873,plasma concentrations,"After removed of the patch, plasma concentrations first increased from 15.8 +/- 28.6 ng/ml (at 24 h) to 21.4 +/- 36.7 ng/ml, then decreased with an elimination half-life of 0.7 +/- 0.2 h.",Development and in vivo assessment of a transdermal system for physostigmine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9789873/),[ng] / [ml],21.4,158499,DB00981,Physostigmine
,9789873,elimination half-life,"After removed of the patch, plasma concentrations first increased from 15.8 +/- 28.6 ng/ml (at 24 h) to 21.4 +/- 36.7 ng/ml, then decreased with an elimination half-life of 0.7 +/- 0.2 h.",Development and in vivo assessment of a transdermal system for physostigmine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9789873/),h,0.7,158500,DB00981,Physostigmine
,9789873,inhibition percentages,AChE inhibition percentages increased from 6.5 +/- 2.3% to 16.0 +/- 27.7%.,Development and in vivo assessment of a transdermal system for physostigmine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9789873/),%,6.5,158501,DB00981,Physostigmine
,9789873,inhibition percentages,AChE inhibition percentages increased from 6.5 +/- 2.3% to 16.0 +/- 27.7%.,Development and in vivo assessment of a transdermal system for physostigmine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9789873/),%,16.0,158502,DB00981,Physostigmine
,9499573,plasma protein binding,"The geometric mean plasma protein binding was 55% and 66%, respectively, for (+)-(R)- and (-)-(S)-thalidomide.",Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9499573/),%,55,159497,DB00981,Physostigmine
,9499573,plasma protein binding,"The geometric mean plasma protein binding was 55% and 66%, respectively, for (+)-(R)- and (-)-(S)-thalidomide.",Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9499573/),%,66,159498,DB00981,Physostigmine
,2891478,alpha-half-life,"The alpha-half-life and the beta-half-life were 1.31 and 15.01 min, respectively.",Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891478/),min,1.31,160854,DB00981,Physostigmine
,2891478,beta-half-life,"The alpha-half-life and the beta-half-life were 1.31 and 15.01 min, respectively.",Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891478/),min,15.01,160855,DB00981,Physostigmine
,2891478,apparent volume of distribution,The apparent volume of distribution was found to be 270 ml.,Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891478/),ml,270,160856,DB00981,Physostigmine
,2891478,clearance,The clearance was 12.43 ml min-1.,Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891478/),[ml] / [min],12.43,160857,DB00981,Physostigmine
,2891478,half-life,The half-life of Phy in brain was 11 min.,Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891478/),min,11,160858,DB00981,Physostigmine
,2891478,brain to plasma ratio,The brain to plasma ratio (1.69) peaked at 15 min.,Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891478/),,1.69,160859,DB00981,Physostigmine
,2891478,maximum inhibition,The maximum inhibition of BuChE (52%) correlates with the highest Phy concentration (84.6 ng/ml) in plasma at 2 min and 70% of the enzymic activity recovered by 45 min.,Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891478/),%,52,160860,DB00981,Physostigmine
,2891478,maximum inhibition,"The maximum inhibition of ChE (63%) in the brain correlates with the highest Phy concentration (128 ng/g) at 3 min, and 85% of the enzymic activity was recovered within an hour.",Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891478/),%,63,160861,DB00981,Physostigmine
,11261809,half-lives,"Following i.v. dosing, brain drug levels were 10-fold higher than those achieved in plasma, peaked within 5 min and rapidly declined with half-lives of 8.5 and 12.6 min, respectively.",The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11261809/),min,8.5,169162,DB00981,Physostigmine
,11261809,half-lives,"Following i.v. dosing, brain drug levels were 10-fold higher than those achieved in plasma, peaked within 5 min and rapidly declined with half-lives of 8.5 and 12.6 min, respectively.",The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11261809/),min,12.6,169163,DB00981,Physostigmine
>,11261809,half-life,"In contrast, a high (> 70%) and long-lasting inhibition of AChE was achieved (half-life > 8.25 h).",The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11261809/),h,8.25,169164,DB00981,Physostigmine
,11261809,oral bioavailability,A comparison between the time-dependent plasma AChE inhibition achieved after similar oral and i.v. doses provided an estimate of oral bioavailability of 100%.,The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11261809/),%,100,169165,DB00981,Physostigmine
,3658115,maximal inhibition,The maximal inhibition of ChE (78%) in plasma at 2 min correlated with the largest concentration of physostigmine (124 ng/ml).,Pharmacokinetics and pharmacodynamics of physostigmine after intravenous administration in beagle dogs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3658115/),%,78,189656,DB00981,Physostigmine
,3658115,elimination half-life (beta),The elimination half-life (beta) was 30.7 min in the dog as compared to 15 min in rat and and 21.7 min in man.,Pharmacokinetics and pharmacodynamics of physostigmine after intravenous administration in beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3658115/),min,30.7,189657,DB00981,Physostigmine
,3658115,elimination half-life (beta),The elimination half-life (beta) was 30.7 min in the dog as compared to 15 min in rat and and 21.7 min in man.,Pharmacokinetics and pharmacodynamics of physostigmine after intravenous administration in beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3658115/),min,15,189658,DB00981,Physostigmine
,3658115,elimination half-life (beta),The elimination half-life (beta) was 30.7 min in the dog as compared to 15 min in rat and and 21.7 min in man.,Pharmacokinetics and pharmacodynamics of physostigmine after intravenous administration in beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3658115/),min,21.7,189659,DB00981,Physostigmine
,3658115,Vd,"The Vd (ml/kg) was higher than total body water volume in all three species: dog (1832), rat (1352) and man (664), indicating sequestration of the drug in body compartments.",Pharmacokinetics and pharmacodynamics of physostigmine after intravenous administration in beagle dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3658115/),[ml] / [kg],1832,189660,DB00981,Physostigmine
,3658115,Vd,"The Vd (ml/kg) was higher than total body water volume in all three species: dog (1832), rat (1352) and man (664), indicating sequestration of the drug in body compartments.",Pharmacokinetics and pharmacodynamics of physostigmine after intravenous administration in beagle dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3658115/),[ml] / [kg],135,189661,DB00981,Physostigmine
,3658115,Vd,"The Vd (ml/kg) was higher than total body water volume in all three species: dog (1832), rat (1352) and man (664), indicating sequestration of the drug in body compartments.",Pharmacokinetics and pharmacodynamics of physostigmine after intravenous administration in beagle dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3658115/),[ml] / [kg],66,189662,DB00981,Physostigmine
,3658115,Clearance,"Clearance (ml/min/kg) was found to be 41.2 in dog, which compares to 62 in rat and 22 in man.",Pharmacokinetics and pharmacodynamics of physostigmine after intravenous administration in beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3658115/),[ml] / [kg·min],41.2,189663,DB00981,Physostigmine
,3658115,Clearance,"Clearance (ml/min/kg) was found to be 41.2 in dog, which compares to 62 in rat and 22 in man.",Pharmacokinetics and pharmacodynamics of physostigmine after intravenous administration in beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3658115/),[ml] / [kg·min],62,189664,DB00981,Physostigmine
,3658115,Clearance,"Clearance (ml/min/kg) was found to be 41.2 in dog, which compares to 62 in rat and 22 in man.",Pharmacokinetics and pharmacodynamics of physostigmine after intravenous administration in beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3658115/),[ml] / [kg·min],22,189665,DB00981,Physostigmine
,22077248,half-life,In 13 cases quetiapine was analysed quantitatively in serum with a relevantly prolonged half-life (16 ± 12 h) and a median peak serum concentration of 3074 ng/mL.,Clinical and analytical features of severe suicidal quetiapine overdoses--a retrospective cohort study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22077248/),h,16,199504,DB00981,Physostigmine
,22077248,peak serum concentration,In 13 cases quetiapine was analysed quantitatively in serum with a relevantly prolonged half-life (16 ± 12 h) and a median peak serum concentration of 3074 ng/mL.,Clinical and analytical features of severe suicidal quetiapine overdoses--a retrospective cohort study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22077248/),[ng] / [ml],3074,199505,DB00981,Physostigmine
,7608318,AUC0-24,"Eptastigmine plasma concentrations increased proportionally with the dose (mean +/- SEM AUC0-24 was 0.74 +/- 0.58, 3.61 +/- 1.15, and 6.25 +/- 1.51 ng.h/mL with 10, 20, and 30 mg, respectively) and were undetectable at 24 hours.",Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608318/),[h·ng] / [ml],0.74,203561,DB00981,Physostigmine
,7608318,AUC0-24,"Eptastigmine plasma concentrations increased proportionally with the dose (mean +/- SEM AUC0-24 was 0.74 +/- 0.58, 3.61 +/- 1.15, and 6.25 +/- 1.51 ng.h/mL with 10, 20, and 30 mg, respectively) and were undetectable at 24 hours.",Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608318/),[h·ng] / [ml],3.61,203562,DB00981,Physostigmine
,7608318,AUC0-24,"Eptastigmine plasma concentrations increased proportionally with the dose (mean +/- SEM AUC0-24 was 0.74 +/- 0.58, 3.61 +/- 1.15, and 6.25 +/- 1.51 ng.h/mL with 10, 20, and 30 mg, respectively) and were undetectable at 24 hours.",Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608318/),[h·ng] / [ml],6.25,203563,DB00981,Physostigmine
,7608318,peak inhibition,"The inhibition of acetyl-cholinesterase was dose-dependent (peak inhibition was 15 +/- 2%, 30 +/- 4%, and 36 +/- 6% with 10, 20, and 30 mg, respectively) and long-lasting, with a residual inhibition of 8 to 11% at 24 hours.",Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608318/),%,15,203564,DB00981,Physostigmine
,7608318,peak inhibition,"The inhibition of acetyl-cholinesterase was dose-dependent (peak inhibition was 15 +/- 2%, 30 +/- 4%, and 36 +/- 6% with 10, 20, and 30 mg, respectively) and long-lasting, with a residual inhibition of 8 to 11% at 24 hours.",Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608318/),%,30,203565,DB00981,Physostigmine
,7608318,peak inhibition,"The inhibition of acetyl-cholinesterase was dose-dependent (peak inhibition was 15 +/- 2%, 30 +/- 4%, and 36 +/- 6% with 10, 20, and 30 mg, respectively) and long-lasting, with a residual inhibition of 8 to 11% at 24 hours.",Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608318/),%,36,203566,DB00981,Physostigmine
,7608318,peak inhibition,"Butyryl-cholinesterase inhibition was weak and not dose-dependent (peak inhibition was 12 +/- 4%, 13 +/- 3%, and 12 +/- 2% with 10, 20, and 30 mg, respectively).",Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608318/),%,12,203567,DB00981,Physostigmine
,7608318,peak inhibition,"Butyryl-cholinesterase inhibition was weak and not dose-dependent (peak inhibition was 12 +/- 4%, 13 +/- 3%, and 12 +/- 2% with 10, 20, and 30 mg, respectively).",Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608318/),%,13,203568,DB00981,Physostigmine
,7608318,peak inhibition,"Butyryl-cholinesterase inhibition was weak and not dose-dependent (peak inhibition was 12 +/- 4%, 13 +/- 3%, and 12 +/- 2% with 10, 20, and 30 mg, respectively).",Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608318/),%,12,203569,DB00981,Physostigmine
,11165084,nasal bioavailability,The nasal bioavailability of NXX-066 was 100+/-30% and the elimination from plasma was as rapid as that following intravenous administration.,Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer's disease to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165084/),,100,220110,DB00981,Physostigmine
,7756100,lag-time,2. A single application of the patch over 24 h produced detectable plasma drug concentrations after a mean lag-time of 4 h.,Pharmacokinetics of physostigmine in man following a single application of a transdermal system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756100/),h,4,223145,DB00981,Physostigmine
,7756100,absolute bioavailability,3. A mean absolute bioavailability of 36% was determined for the transdermal system and 3% for the oral solution.,Pharmacokinetics of physostigmine in man following a single application of a transdermal system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756100/),%,36,223146,DB00981,Physostigmine
,7756100,absolute bioavailability,3. A mean absolute bioavailability of 36% was determined for the transdermal system and 3% for the oral solution.,Pharmacokinetics of physostigmine in man following a single application of a transdermal system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756100/),%,3,223147,DB00981,Physostigmine
,7756100,apparent half-life of elimination,"5. After removing the PTS, the mean apparent half-life of elimination was 4.9 h, compared with 0.5 h for the i.v. infusion.",Pharmacokinetics of physostigmine in man following a single application of a transdermal system. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756100/),h,4.9,223148,DB00981,Physostigmine
,7756100,apparent half-life of elimination,"5. After removing the PTS, the mean apparent half-life of elimination was 4.9 h, compared with 0.5 h for the i.v. infusion.",Pharmacokinetics of physostigmine in man following a single application of a transdermal system. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756100/),h,0.5,223149,DB00981,Physostigmine
,11514953,AUC,"After a 1-min intravenous infusion of parathion to rats pretreated with physostigmine, the AUC of parathion (60.4 compared with 73.7 microg min/mL) was significantly greater, Cl of parathion (49.7 compared with 40.7 mL/min/kg) was significantly slower, and amount of paraoxon recovered from liver, mesentery and large intestine at 5 min was smaller than those in control rats.",Effects of physostigmine on the pharmacokinetics of intravenous parathion in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11514953/),[min·μg] / [ml],60.4,230643,DB00981,Physostigmine
,11514953,AUC,"After a 1-min intravenous infusion of parathion to rats pretreated with physostigmine, the AUC of parathion (60.4 compared with 73.7 microg min/mL) was significantly greater, Cl of parathion (49.7 compared with 40.7 mL/min/kg) was significantly slower, and amount of paraoxon recovered from liver, mesentery and large intestine at 5 min was smaller than those in control rats.",Effects of physostigmine on the pharmacokinetics of intravenous parathion in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11514953/),[min·μg] / [ml],73.7,230644,DB00981,Physostigmine
,11514953,Cl,"After a 1-min intravenous infusion of parathion to rats pretreated with physostigmine, the AUC of parathion (60.4 compared with 73.7 microg min/mL) was significantly greater, Cl of parathion (49.7 compared with 40.7 mL/min/kg) was significantly slower, and amount of paraoxon recovered from liver, mesentery and large intestine at 5 min was smaller than those in control rats.",Effects of physostigmine on the pharmacokinetics of intravenous parathion in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11514953/),[ml] / [kg·min],49.7,230645,DB00981,Physostigmine
,11514953,Cl,"After a 1-min intravenous infusion of parathion to rats pretreated with physostigmine, the AUC of parathion (60.4 compared with 73.7 microg min/mL) was significantly greater, Cl of parathion (49.7 compared with 40.7 mL/min/kg) was significantly slower, and amount of paraoxon recovered from liver, mesentery and large intestine at 5 min was smaller than those in control rats.",Effects of physostigmine on the pharmacokinetics of intravenous parathion in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11514953/),[ml] / [kg·min],40.7,230646,DB00981,Physostigmine
,11514953,activity,"Based on in vitro rat hepatic microsomal studies, physostigmine inhibited significantly the erythromycin N-demethylase activity (1.03 compared with 0.924 nmol/mg protein/min), mainly mediated by hepatic cytochrome P450 3A in rats.",Effects of physostigmine on the pharmacokinetics of intravenous parathion in rats. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11514953/),[nM] / [·mg·min],1.03,230647,DB00981,Physostigmine
,11514953,activity,"Based on in vitro rat hepatic microsomal studies, physostigmine inhibited significantly the erythromycin N-demethylase activity (1.03 compared with 0.924 nmol/mg protein/min), mainly mediated by hepatic cytochrome P450 3A in rats.",Effects of physostigmine on the pharmacokinetics of intravenous parathion in rats. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11514953/),[nM] / [·mg·min],0.924,230648,DB00981,Physostigmine
,1635892,terminal half-life,"After a single dose, heptastigmine remained for a long time in plasma (the terminal half-life was about 12 h), distributed widely in tissues (the volume of distribution was about 61) and brain concentrations were very high (4-22 times those found in plasma).",Pharmacokinetics of heptastigmine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635892/),h,12,232887,DB00981,Physostigmine
,1635892,volume of distribution,"After a single dose, heptastigmine remained for a long time in plasma (the terminal half-life was about 12 h), distributed widely in tissues (the volume of distribution was about 61) and brain concentrations were very high (4-22 times those found in plasma).",Pharmacokinetics of heptastigmine in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635892/),,61,232888,DB00981,Physostigmine
,3705906,plasma clearance,After intravenous administration physostigmine had a very rapid plasma elimination with a plasma clearance ranging from 47 to 163 l/h with a mean +/- s.d. of 92.5 +/- 37.7 l/h.,"Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705906/),[l] / [h],47 to 163,241911,DB00981,Physostigmine
,3705906,plasma clearance,After intravenous administration physostigmine had a very rapid plasma elimination with a plasma clearance ranging from 47 to 163 l/h with a mean +/- s.d. of 92.5 +/- 37.7 l/h.,"Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705906/),[l] / [h],92.5,241912,DB00981,Physostigmine
,3705906,volume of distribution,"The volume of distribution was 46.5 +/- 19.2 l, while distribution and plasma elimination half-lives were 2.3 and 22 min, respectively.","Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705906/),l,46.5,241913,DB00981,Physostigmine
,3705906,distribution,"The volume of distribution was 46.5 +/- 19.2 l, while distribution and plasma elimination half-lives were 2.3 and 22 min, respectively.","Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705906/),min,2.3,241914,DB00981,Physostigmine
,3705906,plasma elimination half-lives,"The volume of distribution was 46.5 +/- 19.2 l, while distribution and plasma elimination half-lives were 2.3 and 22 min, respectively.","Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705906/),min,22,241915,DB00981,Physostigmine
,3705906,blood elimination half-life,A fraction of the dose was probably hydrolyzed in blood since its blood elimination half-life in vitro was approximately 190 min.,"Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705906/),min,190,241916,DB00981,Physostigmine
,8128833,elimination half-life,"The original compound in this class, physostigmine has an elimination half-life of 20-30 min.",Pharmacokinetic studies of cholinesterase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8128833/),min,20-30,246699,DB00981,Physostigmine
,8128833,elimination half-lives,"Galanthamine, tacrine and the metabolite 1-hydroxytacrine (velnacrine) have longer elimination half-lives of 1.6-6 hours mainly due to a larger volume of distribution.",Pharmacokinetic studies of cholinesterase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8128833/),h,1.6-6,246700,DB00981,Physostigmine
,16248851,MTD,The MTD of phenserine tartrate was 10 mg.,Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16248851/),mg,10,247715,DB00981,Physostigmine
,16248851,Cmax,"Subjects receiving 10 mg of phenserine tartrate had a Cmax of 1.95 ng/mL at 1.5 hours, and the mean peak inhibition (Imax) of AChE was 26% (range: 18-34%) at 1.75 hours (tImax) following dosing.",Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16248851/),[ng] / [ml],1.95,247716,DB00981,Physostigmine
,16248851,peak inhibition (Imax),"Subjects receiving 10 mg of phenserine tartrate had a Cmax of 1.95 ng/mL at 1.5 hours, and the mean peak inhibition (Imax) of AChE was 26% (range: 18-34%) at 1.75 hours (tImax) following dosing.",Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16248851/),%,26,247717,DB00981,Physostigmine
,16248851,half-life of AChE inhibition (tI1/2),The half-life of AChE inhibition (tI1/2) was 11 hours.,Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16248851/),h,11,247718,DB00981,Physostigmine
,9681667,maximum acetylcholinesterase inhibition (Imax),Mean maximum acetylcholinesterase inhibition (Imax) was 39.9% after eptastigmine without food and 33.1% after eptastigmine with food.,Effect of food on the absorption of eptastigmine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9681667/),%,39.9,258861,DB00981,Physostigmine
,9681667,maximum acetylcholinesterase inhibition (Imax),Mean maximum acetylcholinesterase inhibition (Imax) was 39.9% after eptastigmine without food and 33.1% after eptastigmine with food.,Effect of food on the absorption of eptastigmine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9681667/),%,33.1,258862,DB00981,Physostigmine
,9681667,Areas under the curve of,Areas under the curve of acetylcholinesterase per cent inhibition from 0 to 8 h after drug administration (AUC0-8) were 198% h after eptastigmine without food and 124% h after eptastigmine with food.,Effect of food on the absorption of eptastigmine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9681667/),%·h,198,258863,DB00981,Physostigmine
,9681667,Areas under the curve of,Areas under the curve of acetylcholinesterase per cent inhibition from 0 to 8 h after drug administration (AUC0-8) were 198% h after eptastigmine without food and 124% h after eptastigmine with food.,Effect of food on the absorption of eptastigmine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9681667/),%·h,124,258864,DB00981,Physostigmine
